Assembly Biosciences (ASMB) Earns Media Impact Score of 0.02
News articles about Assembly Biosciences (NASDAQ:ASMB) have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Assembly Biosciences earned a media sentiment score of 0.02 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 44.0629845106597 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the headlines that may have effected Accern Sentiment’s analysis:
- Assembly Biosciences Inc (ASMB) Expected to Announce Quarterly Sales of $1.68 Million (americanbankingnews.com)
- BidaskClub Lowers Assembly Biosciences (ASMB) to Hold (americanbankingnews.com)
- Assembly Biosciences Inc (ASMB) Given Average Recommendation of “Buy” by Brokerages (americanbankingnews.com)
- Assembly Biosciences (ASMB) Coverage Initiated at B. Riley (americanbankingnews.com)
Assembly Biosciences (ASMB) opened at $44.66 on Friday. The company has a market capitalization of $776.98, a price-to-earnings ratio of -15.04 and a beta of 0.90. Assembly Biosciences has a 52-week low of $12.75 and a 52-week high of $52.37.
ASMB has been the subject of a number of research analyst reports. Zacks Investment Research raised Assembly Biosciences from a “hold” rating to a “buy” rating and set a $37.00 price target for the company in a research note on Wednesday, November 15th. Jefferies Group initiated coverage on Assembly Biosciences in a research note on Wednesday, November 8th. They issued a “buy” rating and a $50.00 price target for the company. BidaskClub lowered Assembly Biosciences from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 6th. ValuEngine lowered Assembly Biosciences from a “hold” rating to a “sell” rating in a research note on Thursday, December 7th. Finally, Chardan Capital reissued a “buy” rating on shares of Assembly Biosciences in a research report on Sunday, September 17th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $39.25.
In other Assembly Biosciences news, Director William R. Ringo sold 1,000 shares of the firm’s stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $29.55, for a total transaction of $29,550.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold 4,000 shares of company stock valued at $157,660 in the last three months. Insiders own 19.60% of the company’s stock.
Assembly Biosciences Company Profile
Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.